XORTX Announces Participation at Upcoming Investor Conferences
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced that its President and CEO, Dr. Allen Davidoff, will speak at several upcoming investor conferences. These include the Sidoti & Company LLC Micro-Cap Virtual Conference on November 9-10, the A.G.P. Virtual Biotech Conference on November 30-December 1, and Singular Research's Best of the Uncovereds Conference on December 8 in San Francisco. XORTX is focused on developing innovative therapies for progressive kidney disease, including drugs like XRx-008 for ADPKD and XRx-101 for COVID-19 related organ injury.
- None.
- None.
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences:
Sidotti & Company LLC - November Micro-Cap Virtual Conference
Registration: Sidoti & Co November 9-10 2022 Micro-Cap Virtual Investor Conference Registration
A.G.P.’s Virtual Biotech Conference
Registration: Alliance Global Partners Nov 30th-Dec 1st 2022 Virtual Biotech Investor Conference Registration
Singular Research’s Best of the Uncovereds
Registration: Singular Research's Best of the Uncovereds Conference Dec. 8th 2022 San Francisco Registration
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead program in XRx-008 for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.
For further information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications | |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 | |
| Media Inquiries, David Melamed, Ph.D. | ||
| david.melamed@russopartnersllc.com or +1 212 845 4225 | ||
The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Forward Looking Statements
This press release may contain express or implied forward-looking statements pursuant to Canadian and U.S. Federal securities laws. These forward-looking statements and their implications are based on the current reasonable expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in such forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained in the Company’s most recently filed Annual Information Form and the Management Discussion and Analysis for its most recent financial reporting period filed on the Company’s SEDAR profile (www.sedar.com) and under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (“SEC”) available on the SEC's website, www.sec.gov.
FAQ
What conferences will XORTX participate in November 2022?
Who is the CEO of XORTX Therapeutics?
What is XORTX's main focus in developing therapies?
What is XORTX's lead program?
What is the stock symbol for XORTX Therapeutics?
